帕金森病的辅助治疗：雷沙吉兰的作用。
Adjunctive therapy in Parkinson's disease: the role of rasagiline.
机构信息
Department of Neurology, Aurora Advanced Healthcare, Milwaukee, WI.
出版信息
Neuropsychiatr Dis Treat. 2012;8:285-94. doi: 10.2147/NDT.S25142. Epub 2012 Jul 2.
Abstract
Parkinson's disease is the second most common neurodegenerative disorder, currently affecting 1.5 million people in the US. In this review, we describe the diagnostic and pathological features of Parkinson's disease, as well as its clinical course. We then review pharmacologic treatments for the disease, with a particular focus on therapies adjunctive to levodopa and specifically the role of rasagiline. We review the four pivotal rasagiline trials, and discuss rasagiline and its use as adjunctive therapy for Parkinson's disease. Finally, we discuss potential side effects, drug interactions, and other practical aspects concerning the use of rasagiline in Parkinson's disease.
摘要
帕金森病是第二常见的神经退行性疾病，目前影响美国 150 万人。在这篇综述中，我们描述了帕金森病的诊断和病理学特征及其临床过程。然后，我们回顾了该疾病的药物治疗方法，特别关注左旋多巴辅助治疗以及雷沙吉兰的作用。我们回顾了四项关键性雷沙吉兰试验，并讨论了雷沙吉兰及其作为帕金森病辅助治疗的用途。最后，我们讨论了雷沙吉兰在帕金森病中的使用的潜在副作用、药物相互作用和其他实际问题。
相似文献
1
Adjunctive therapy in Parkinson's disease: the role of rasagiline.
Neuropsychiatr Dis Treat. 2012;8:285-94. doi: 10.2147/NDT.S25142. Epub 2012 Jul 2.
2
Successful use of rasagiline in combination with two antidepressants: a case report.
Innov Clin Neurosci. 2012 Nov;9(11-12):39-41.
3
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Parkinsonism Relat Disord. 2018 Aug;53:21-27. doi: 10.1016/j.parkreldis.2018.04.025. Epub 2018 Apr 27.
4
Spotlight on rasagiline in Parkinson's disease.
CNS Drugs. 2008;22(1):83-6. doi: 10.2165/00023210-200822010-00007.
5
Rasagiline: a review of its use in the management of Parkinson's disease.
Drugs. 2007;67(12):1725-47. doi: 10.2165/00003495-200767120-00006.
6
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
J Neural Transm (Vienna). 2019 Mar;126(3):289-297. doi: 10.1007/s00702-018-1962-5. Epub 2019 Jan 11.
7
[Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect)].
Nihon Yakurigaku Zasshi. 2020;155(3):187-194. doi: 10.1254/fpj.19146.
8
Rasagiline: a guide to its use in Parkinson's disease.
CNS Drugs. 2012 Sep 1;26(9):781-5. doi: 10.2165/11207570-000000000-00000.
9
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Clin Neuropharmacol. 2000 Nov-Dec;23(6):324-30. doi: 10.1097/00002826-200011000-00005.
10
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Lancet. 2005;365(9463):947-54. doi: 10.1016/S0140-6736(05)71083-7.
引用本文的文献
1
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
BMC Neurol. 2023 Oct 6;23(1):360. doi: 10.1186/s12883-023-03411-3.
2
Therapeutic strategies in the early stages of Parkinson's disease: a cross-sectional evaluation of 15 years' experience with a large cohort of Romanian patients.
Neuropsychiatr Dis Treat. 2019 Apr 5;15:831-838. doi: 10.2147/NDT.S197630. eCollection 2019.
本文引用的文献
1
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Mov Disord. 2011 Aug 15;26(10):1851-8. doi: 10.1002/mds.23738. Epub 2011 Apr 15.
2
Pharmacological therapy in Parkinson's disease: focus on neuroprotection.
CNS Neurosci Ther. 2011 Oct;17(5):345-67. doi: 10.1111/j.1755-5949.2010.00150.x. Epub 2010 Apr 23.
3
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
N Engl J Med. 2009 Sep 24;361(13):1268-78. doi: 10.1056/NEJMoa0809335.
4
Is Parkinson's disease a prion disorder?
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12571-2. doi: 10.1073/pnas.0906759106. Epub 2009 Jul 28.
5
Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis.
J Neurochem. 2009 Aug;110(3):1005-13. doi: 10.1111/j.1471-4159.2009.06191.x. Epub 2009 May 29.
6
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Lancet Neurol. 2009 Apr;8(4):382-97. doi: 10.1016/S1474-4422(09)70062-6.
7
Timely levodopa (LD) administration prolongs survival in Parkinson's disease.
Parkinsonism Relat Disord. 1997 Nov;3(3):159-65. doi: 10.1016/s1353-8020(97)00030-8.
8
ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage.
Antioxid Redox Signal. 2007 Dec;9(12):2345-55. doi: 10.1089/ars.2007.1793.
9
Localization of L-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistry.
Brain Res. 2007 Sep 5;1167:56-70. doi: 10.1016/j.brainres.2007.05.081. Epub 2007 Jul 17.
10
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?
Genes Brain Behav. 2008 Mar;7(2):129-51. doi: 10.1111/j.1601-183X.2007.00342.x. Epub 2007 Aug 3.
Zotero 插件